Furiex Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now

Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 1.35%.

Furiex Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-2.32 in the quarter versus EPS of $-2.09 in the year-earlier quarter.

Revenue: Decreased 77.06% to $3 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Furiex Pharmaceuticals, Inc. reported adjusted EPS loss of $2.32 per share. By that measure, the company missed the mean analyst estimate of $-1.65. It missed the average revenue estimate of $11.94 million.

Quoting Management: Fred Eshelman, Pharm.D., chairman of Furiex, added, “The U.S. launch of Nesina, Kazano® and Oseni® on June 17, 2013, the positive CHMP opinion on the alogliptin family of products and the recent marketing authorization from the CFDA, we believe, will add value to the alogliptin franchise and continue to provide an important foundation for our business. We remain on track with the development of eluxadoline and we are one step closer to our goal of filing a New Drug Application with patient enrollment in the Phase III clinical trials now complete.”

Key Stats (on next page)…

Revenue decreased 92.37% from $39.33 million in the previous quarter. EPS decreased to $-2.32 in the quarter versus EPS of $0.82 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.49 to a loss $0.61. For the current year, the average estimate has moved down from a loss of $1.63 to a loss of $1.96 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)